decisionhealth Newsletters, Answer Books - 2008 Issue 5 (May)
Appendix E - National Coverage Determinations Manual / HUMAN_TUMOR_STEM_CELL_DRUG_SENSITIVITY_ASSAYS
Subscribe or sign in to view the full article.
Article Overview
This article summarizes a National Coverage Determinations Manual entry addressing human tumor stem cell drug sensitivity assays and the Fluorescent Cytoprint Assay. It is relevant for readers who follow Medicare coverage policy, oncology-related diagnostic testing, and laboratory medicine guidance, and it explains the general coverage status of these methods.
Why This Topic Matters
It helps readers understand how Medicare classifies certain tumor drug sensitivity and chemosensitivity tests within national coverage policy.
Article Sections
-
Human Tumor Stem Cell Drug Sensitivity Assays
Overview of the topic, including the general purpose of tumor drug sensitivity testing and the coverage status described in the manual entry.
-
Fluorescent Cytoprint Assay
Discussion of a related cancer chemosensitivity testing method and its status within the coverage policy context.
What You Will Learn
- The general subject of tumor drug sensitivity and chemosensitivity testing
- How the article situates these tests within Medicare coverage policy
- Which related assay method is discussed alongside the main topic
- The type of policy resource from which the guidance is drawn
Who Should Read This
- Medical coders
- Coding auditors
- Oncology billing staff
- Laboratory medicine professionals
- Health policy readers
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com